Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T cells in the Presence of Rituximab

CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that residual serum rituximab might block CAR binding to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Rufener, Gregory A., Press, Oliver W., Olsen, Philip, Lee, Sang Yun, Jensen, Michael C., Gopal, Ajay K., Pender, Barbara, Budde, Lihua E., Rossow, Jeffrey K., Green, Damian J., Maloney, David G., Riddell, Stanley R., Till, Brian G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891234/
https://ncbi.nlm.nih.gov/pubmed/27197068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados